EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c. 34G >T (p. G12C ) mutation

Satoko Ugai, Qian Yao, Yasutoshi Takashima, Yuxue Zhong, Kosuke Matsuda, Hidetaka Kawamura, Yu Imamura iD, Kazuo Okadome, Kosuke Mima, Kota Arima, Keisuke Kosumi, Mingyang Song und 5 weitere

Cancer Science · 2024-10 · 115 (10) · 3455-3465

DOI: 10.1111/cas.16262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 22.07.2024. Verfasst von Satoko Ugai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massac…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Mutation, DNA Methylation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Evidence indicates that combinations of anti‐EGFR antibodies and KRAS p.G12C (c.34G>T) inhibitors can be an effective treatment strategy for advanced colorectal cancer. We hypothesized that KRAS c.34G>T (p.G12C)‐mutated colorectal carcinoma might be a distinct tumor subtype. We utilized a prospective cohort incident tumor biobank (including 1347 colorectal carcinomas) and detected KRAS c.34G>T (p.G12C) mutation in 43 cases (3.2%) and other KRAS mutations (in codon 12, 13, 61, or 146) in 467 cases (35%). The CpG island methylator phenotype (CIMP)‐low prevalence was similarly higher in KRAS c.34G>T mutants (52%) and other KRAS mutants (49%) than in KRAS ‐wild‐type tumors (31%). KRAS c.34G>T mutants showed higher CIMP‐high prevalence (14%) and lower CIMP‐negative prevalence (33%) compared with other KRAS mutants (6% and 45%, respectively; p = 0.0036). Similar to other KRAS mutants, KRAS c.34G>T‐mutated tumors were associated with cecal location, non‐microsatellite instability (MSI)‐high status, BRAF wild type, and PIK3CA mutation when compared with KRAS ‐wild‐type tumors. Compared with BRAF ‐mutated tumors, KRAS c.34G>T mutants showed more frequent LINE‐1 hypomethylation, a biomarker for early‐onset colorectal carcinoma. KRAS c.34G>T mutants were not associated with other features, including the tumor tissue abundance of Fusobacterium nucleatum ( F. animalis ), pks + Escherichia coli , Bifidobacterium , or (enterotoxigenic) Bacteroides fragilis . Among 1122 BRAF ‐wild‐type colorectal carcinomas, compared with KRAS ‐wild‐type tumors, multivariable‐adjusted colorectal cancer‐specific mortality hazard ratios (95% confidence interval) were 1.82 (1.05–3.17) in KRAS c.34G>T (p.G12C)‐mutated tumors ( p = 0.035) and 1.57 (1.22–2.02) in other KRAS ‐mutated tumors ( p = 0.0004). Our study provides novel evidence for clinical and tumor characteristics of KRAS c.34G>T (p.G12C)‐mutated colorectal carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProto-Oncogene Proteins p21(ras)MutationDNA MethylationCpG IslandsHumansFemaleMaleAgedMiddle AgedPrognosisProspective StudiesProto-Oncogene Proteins B-rafAged, 80 and overAdultClass I Phosphatidylinositol 3-KinasesMicrosatellite Instability

Stichwörter der Autor:innen

KRASCpG island methylator phenotypeadagrasibcolorectal tumorsotorasib

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesBRAF protein, humanPIK3CA protein, human

Autor:innen und Institutionen

  • Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical, Boston, Massachusetts, USA.
  • Department of Surgery, Fukushima Medical University, Fukushima, Japan.
  • Department of Esophageal Surgery, The Cancer Institute Hospital of the Japanese Foundation of Cancer Research, Tokyo, Japan.
  • Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

ORCID-Profile: Yu Imamura, Tomotaka Ugai

Förderung

  • Cancer Research UK
  • NCI NIH HHS

Zitieren

APA

Ugai, S., Yao, Q., Takashima, Y., Zhong, Y., Matsuda, K., Kawamura, H., Imamura, Y., Okadome, K., Mima, K., Arima, K., Kosumi, K., Song, M., Meyerhardt, J. A., Giannakis, M., Nowak, J. A., Ugai, T., & Ogino, S. (2024). Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c. 34G >T (p. G12C ) mutation. Cancer Science, 115(10), 3455-3465. https://doi.org/10.1111/cas.16262

Vancouver

Ugai S, Yao Q, Takashima Y, Zhong Y, Matsuda K, Kawamura H, et al. Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c. 34G >T (p. G12C ) mutation. Cancer Science. 2024;115(10):3455-3465. doi:10.1111/cas.16262

BibTeX
@article{Ugai2024,
  author = {Ugai, Satoko and Yao, Qian and Takashima, Yasutoshi and Zhong, Yuxue and Matsuda, Kosuke and Kawamura, Hidetaka and Imamura, Yu and Okadome, Kazuo and Mima, Kosuke and Arima, Kota and Kosumi, Keisuke and Song, Mingyang and Meyerhardt, Jeffrey A and Giannakis, Marios and Nowak, Jonathan A and Ugai, Tomotaka and Ogino, Shuji},
  title = {Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c. 34G >T (p. G12C ) mutation},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {10},
  pages = {3455--3465},
  doi = {10.1111/cas.16262}
}
Kostenlos starten →